What is Elminda?
Elminda, operating at the intersection of artificial intelligence and neurology, provides FDA-cleared technology designed to transform how healthcare professionals diagnose and manage cognitive disorders. The company's core offering, BNA, utilizes a proprietary database to deliver objective, data-driven insights into brain function. By providing clinicians with actionable biomarkers, Elminda addresses a critical gap in neurological care, moving the industry away from subjective assessments toward precise, quantitative diagnostics. This technological edge positions the firm as a pivotal player in the evolving landscape of digital health and neuro-biomarker development.
How much funding has Elminda raised?
Elminda has raised a total of $28M across 1 funding round:
Series C
$28M
Series C (2015): $28M with participation from Healthcrest AG, Shanda Group, OurCrowd, WR Hambrecht, Wexford Capital, and Palisade Capital Management
Key Investors in Elminda
Healthcrest AG
A private equity partner and strategic advisor founded by seasoned entrepreneurs with deep expertise in the global medical device and pharmaceutical sectors.
Shanda Group
A Beijing-based investment firm with a significant footprint in the software and technology sectors, providing capital to support high-growth innovation.
OurCrowd
An Israel-based investment platform that connects accredited investors and institutions with early-stage companies and venture funds.
What's next for Elminda?
With the support of its latest capital injection, Elminda is well-positioned to scale its operational footprint and accelerate the adoption of its BNA technology across global healthcare systems. The company's strategic roadmap likely involves expanding its biomarker database and deepening its integration with existing clinical workflows to enhance patient outcomes. As the demand for objective neuro-diagnostic tools grows, Elminda's focus will remain on refining its AI algorithms and securing further regulatory milestones to maintain its competitive advantage in the high-growth neuro-analytics market.
See full Elminda company page
